

SAFETY DATA SHEET

1. Identification

Product identifier	RYTHMOL TABLETS
Other means of identification	Not available.
Synonym(s)	RYTHMOL 150 MG TABLETS * RYTHMOL 225 MG TABLETS * RYTHMOL 300 MG TABLETS * PROPafenone hydrochloride, formulated product
Recommended use	Medicinal Product
	This safety data sheet is written to provide health, safety and environmental information for people handling this formulated product in the workplace. It is not intended to provide information relevant to medicinal use of the product. In this instance patients should consult prescribing information/package insert/product label or consult their pharmacist or physician. For health and safety information for individual ingredients used during manufacturing, refer to the appropriate safety data sheet for each ingredient.
Recommended restrictions	No other uses are advised.

Manufacturer/Importer/Supplier/Distributor information

Manufacturer

GlaxoSmithKline US
 5 Moore Drive
 Research Triangle Park, NC 27709 USA
 US General Information (normal business hours): +1-888-825-5249
 Email Address: msds@gsk.com
 Website: www.gsk.com
 EMERGENCY PHONE NUMBERS -
 TRANSPORT EMERGENCIES:-
 US / International toll call +1 703 527 3887
 available 24 hrs/7 days; multi-language response

2. Hazard(s) identification

Classified hazards

Exempt from requirements - product regulated as a medicinal product, cosmetic product or medical device.

Label elements

Exempt from requirements - product regulated as a medicinal product, cosmetic product or medical device.

Hazard(s) not otherwise classified (HNOC)

Exempt from requirements - product regulated as a medicinal product, cosmetic product or medical device.

3. Composition/information on ingredients

Mixtures

Hazardous components		Common name and synonyms	CAS number	%
PROPAFENONE	HYDROCHLORIDE	GF119411A 2'-(2-HYDROXY-3-(PROPYLAMINO)PROPO HYDROCHLORIDE	34183-22-7	72.25

Hazardous components Chemical name	Common name and synonyms	CAS number	%
STARCH	AMAZE AMYLOMAIZE AMYLON AMYLUUM ARROWROOT STARCH CLARO CLEARJEL CORN STARCH FARINEX HYLON IMPERMEX MAIZENA MARANTA MIRA QUICK C PASSELI PENFORD GUM POTATO STARCH RICE STARCH ALPHA-STARCH OMC SPRAY POWDERS- ALL GRADES OHS21875 RTECS GM5090000	9005-25-8	10 - < 20
POLYETHYLENE GLYCOL	AZIRIDINE, HOMOPOLYMER, ETHOXYLATED OHS19172	68130-99-4	2.76
TITANIUM DIOXIDE	ANATASE BROOKITE RUTILE TITANIUM OXIDE TITANIUM DIOXIDE (TiO ₂) C.I. PIGMENT WHITE 6 C.I. 77891 TITANIUM(IV) OXIDE TITANIUM(4+) OXIDE TITANIUM PEROXIDE (TiO ₂) TITANIA (TiO ₂) PIGMENT WHITE 6 TITANIA KRONOS TITANIC OXIDE O ₂ Ti OHS23510 RTECS XR2275000 DIOXIDO DE TITANIO TITAANOKSIID	13463-67-7	0.69
MAGNESIUM STEARATE	OCTADECANOIC ACID, MAGNESIUM SALT STEARIC ACID, MAGNESIUM SALT MAGNESIUM DISTEARATE DIBASIC MAGNESIUM STEARATE MAGNESIUM DISTEARATE, PURE OCTADECANOIC ACID MAGNESIUM SALT MAGNESIUM OCTADECANOATE C36H70MGO ₄ OHS13505 RTECS WI4390000 MAGNESIUMDISTEARAT	557-04-0	0.5

Other components below reportable levels

3 - < 5

*Designates that a specific chemical identity and/or percentage of composition has been withheld as a trade secret.

4. First-aid measures

Inhalation

In case of accident by inhalation: remove casualty to fresh air and keep at rest. If breathing is difficult, trained personnel should give oxygen. If not breathing, give artificial respiration. Get medical attention if symptoms occur.

Skin contact

Immediately flush skin with plenty of water. Take off contaminated clothing and wash before reuse. Get medical attention if symptoms occur.

Eye contact

Immediately flush eyes with plenty of water for at least 15 minutes. Get medical attention if irritation develops and persists.

Ingestion

If swallowed, rinse mouth with water (only if the person is conscious). If ingestion of a large amount does occur, call a poison control center immediately.

Most important symptoms/effects, acute and delayed	The following adverse effects have been noted with therapeutic use of this material: irregular heartbeat; temporary decrease in white blood cell count; sensation of bitter taste; dizziness; nausea; vomiting; constipation.
Indication of immediate medical attention and special treatment needed	No specific antidotes are recommended. Treat according to locally accepted protocols. For additional guidance, refer to the current prescribing information or to the local poison control information centre.
General information	Ensure that medical personnel are aware of the material(s) involved, and take precautions to protect themselves. Pre-placement and periodic health surveillance is not usually indicated. The final determination of the need for health surveillance should be determined by local risk assessment.

5. Fire-fighting measures

Suitable extinguishing media	Water spray. Water fog. Foam. Dry chemical powder. Carbon dioxide (CO2).
Unsuitable extinguishing media	None known.
Specific hazards arising from the chemical	During fire, gases hazardous to health may be formed.
Special protective equipment and precautions for firefighters	Self-contained breathing apparatus and full protective clothing must be worn in case of fire.
Fire-fighting equipment/instructions	In the event of fire, cool tanks with water spray.
Specific methods	Cool containers exposed to flames with water until well after the fire is out.

6. Accidental release measures

Personal precautions, protective equipment and emergency procedures	Keep unnecessary personnel away. Keep people away from and upwind of spill/leak. Keep out of low areas. Wear appropriate personal protective equipment. Do not touch damaged containers or spilled material unless wearing appropriate protective clothing. Ensure adequate ventilation. Local authorities should be advised if significant spillages cannot be contained. For personal protection, see section 8 of the MSDS.
Methods and materials for containment and cleaning up	Stop the flow of material, if this is without risk. Prevent entry into waterways, sewer, basements or confined areas. Following product recovery, flush area with water. For waste disposal, see section 13 of the MSDS.
Environmental precautions	Avoid discharge into drains, water courses or onto the ground.

7. Handling and storage

Precautions for safe handling	Do not taste or swallow. Avoid prolonged exposure. Provide adequate ventilation. Wear appropriate personal protective equipment. Observe good industrial hygiene practices. When using, do not eat, drink or smoke. Wash hands thoroughly after handling.
Conditions for safe storage, including any incompatibilities	Store in original tightly closed container. Store in a cool, dry place out of direct sunlight. Store away from incompatible materials (see Section 10 of the MSDS).

8. Exposure controls/personal protection

Occupational exposure limits

GSK Components	Type	Value	Note
MAGNESIUM STEARATE (CAS 557-04-0)	OHC	1	
PROPAFENONE	OHC	2	>100 - <=1000 mcg/m3
HYDROCHLORIDE (CAS 34183-22-7)			

US. OSHA Table Z-1 Limits for Air Contaminants (29 CFR 1910.1000)

Components	Type	Value	Form
STARCH (CAS 9005-25-8)	PEL	5 mg/m3 15 mg/m3	Respirable fraction. Total dust.
TITANIUM DIOXIDE (CAS 13463-67-7)	PEL	15 mg/m3	Total dust.

US. ACGIH Threshold Limit Values

Components	Type	Value
MAGNESIUM STEARATE (CAS 557-04-0)	TWA	10 mg/m3
STARCH (CAS 9005-25-8)	TWA	10 mg/m3
TITANIUM DIOXIDE (CAS 13463-67-7)	TWA	10 mg/m3

US. NIOSH: Pocket Guide to Chemical Hazards
Components **Type**

Value **Form**

5 mg/m³
10 mg/m³

Respirable.
Total

Biological limit values	No biological exposure limits noted for the ingredient(s).
Appropriate engineering controls	An Exposure Control Approach (ECA) is established for operations involving this material based upon the OEL/Occupational Hazard Category and the outcome of a site- or operation-specific risk assessment. Good general ventilation (typically 10 air changes per hour) should be used. Ventilation rates should be matched to conditions. If applicable, use process enclosures, local exhaust ventilation, or other engineering controls to maintain airborne levels below recommended exposure limits. If exposure limits have not been established, maintain airborne levels to an acceptable level. Ensure adequate ventilation, especially in confined areas.
Individual protection measures, such as personal protective equipment	
Eye/face protection	If contact is likely, safety glasses with side shields are recommended.
Hand protection	The choice of an appropriate glove does not only depend on its material but also on other quality features and is different from one producer to the other. Glove selection must take into account any solvents and other hazards present.
Other	Not normally needed.
Respiratory protection	No personal respiratory protective equipment normally required.
Thermal hazards	Wear appropriate thermal protective clothing, when necessary.
General hygiene considerations	An occupational/industrial hygiene monitoring method has been developed for this material. For advice on suitable monitoring methods, seek guidance from a qualified environment, health and safety professional. When using, do not eat, drink or smoke. Always observe good personal hygiene measures, such as washing after handling the material and before eating, drinking, and/or smoking. Routinely wash work clothing and protective equipment to remove contaminants.

9. Physical and chemical properties

Appearance

Physical state	Solid.
Form	Tablet.
Color	Not available.
Odor	Not available.
Odor threshold	Not available.
pH	Not available.
Melting point/freezing point	Not available.
Initial boiling point and boiling range	Not available.
Flash point	Not available.
Evaporation rate	Not available.
Flammability (solid, gas)	Not available.

Upper/lower flammability or explosive limits

Flammability limit - lower (%)	Not available.
Flammability limit - upper (%)	Not available.
Explosive limit - lower (%)	Not available.
Explosive limit - upper (%)	Not available.
Vapor pressure	Not available.
Vapor density	Not available.
Relative density	Not available.
Solubility(ies)	Not available.
Partition coefficient (n-octanol/water)	Not available.
Auto-ignition temperature	Not available.
Decomposition temperature	Not available.
Viscosity	Not available.

10. Stability and reactivity

Reactivity	The product is stable and non-reactive under normal conditions of use, storage and transport.
Chemical stability	Material is stable under normal conditions.
Possibility of hazardous reactions	No dangerous reaction known under conditions of normal use.
Conditions to avoid	Contact with incompatible materials.
Incompatible materials	Acids.
Hazardous decomposition products	Irritating and/or toxic fumes and gases may be emitted upon the products decomposition.

11. Toxicological information

Information on likely routes of exposure

Ingestion	Health injuries are not known or expected under normal use. May be harmful if swallowed.
Inhalation	Health injuries are not known or expected under normal use. Inhalation of dusts may cause respiratory irritation.
Skin contact	Health injuries are not known or expected under normal use. Dust or powder may irritate the skin.
Eye contact	Health injuries are not known or expected under normal use. Dust or powder may irritate eye tissue.
Symptoms related to the physical, chemical and toxicological characteristics	The following adverse effects have been noted with therapeutic use of this material: irregular heartbeat; temporary decrease in white blood cell count; sensation of bitter taste; dizziness; nausea; vomiting; constipation. No specific target organ effects have been identified.

Information on toxicological effects

Acute toxicity	May be harmful if swallowed.
-----------------------	------------------------------

Components	Species	Test Results
MAGNESIUM STEARATE (CAS 557-04-0)		
Acute		
<i>Oral</i>		
LD50	Rat	> 2000 mg/kg
PROPAFENONE HYDROCHLORIDE (CAS 34183-22-7)		
Acute		
<i>Oral</i>		
	Rat	700 mg/kg
TITANIUM DIOXIDE (CAS 13463-67-7)		
Acute		
<i>Inhalation</i>		
LC50	Rat	6820 mcg/m ³
<i>Oral</i>		
LD50	Rat	> 24 g/kg
Chronic		
<i>Inhalation</i>		
LOEC	Rat	8.6 mg/m ³ , 1 years, TiO ₂ accumulated in interstitial macrophages, aggregated interstitial cells and particle laden macrophages in lymphoid tissue.
NOAEC	Rat	250 mg/m ³ , 2 years, Highest dose 5 mg/m ³ , 24 months
Subacute		
<i>Inhalation</i>		
LOEL	Rat	0.1 - 35 mg/m ³ , 4 weeks, Mild macrophage hyperplasia, no change in bronchio-alveolar lavage fluid.
NOAEC	Guinea pig	26 mg/m ³ , 3 weeks, No evidence of significant inflammation in respiratory tract.
<i>Oral</i>		
NOAEL	Rat	100000 ppm, 14 Day, Dietary study, highest dose tested.

Components	Species	Test Results
Subchronic		
<i>Inhalation</i>		
LOEC	Rat	3.2 - 20 mg/m3, 8 min, Accumulation of TiO2 in macrophages and evidence of pulmonary inflammation.
* Estimates for product may be based on additional component data not shown.		
Skin corrosion/irritation	Health injuries are not known or expected under normal use.	
Irritation Corrosion - Skin		
TITANIUM DIOXIDE		Acute dermal irritation; OECD 404, Literature data Result: Non-irritant Species: Rabbit Literature data Result: Non-irritant Species: Guinea pig Literature data Result: Non-irritant Species: Human
Irritation Corrosion - Skin: P.I.I. value		0
MAGNESIUM STEARATE		
Serious eye damage/eye irritation	Health injuries are not known or expected under normal use. Dust or powder may irritate eye tissue.	
Eye		
TITANIUM DIOXIDE		OECD 405, Literature data Result: Mild irritant Species: Rabbit
Eye / Kay and Calandra class - Intact		
MAGNESIUM STEARATE		4 Recovery Period: 2 days
Respiratory sensitization	Not available.	
Skin sensitization	Health injuries are not known or expected under normal use.	
Sensitization		
TITANIUM DIOXIDE		5 % Optimisation Test, Literature data - Vehicle: petrolatum Result: Negative Species: Guinea pig Test Duration: 48 hour exposure Patch test, Literature data Result: Negative Species: Human
Germ cell mutagenicity	No data available to indicate product or any components present at greater than 0.1% are mutagenic or genotoxic.	
PROPAFENONE HYDROCHLORIDE		Ames Assay, Literature data Result: Negative
TITANIUM DIOXIDE		Ames, Literature data Result: Negative
PROPAFENONE HYDROCHLORIDE		Chromosomal Aberration Assay In Vitro, human lymphocytes, Literature data Result: Negative Chromosomal Aberration Assay In Vivo, bone marrow, Literature data Result: Negative Species: Hamster Chromosomal Aberration Assay In Vivo, bone marrow, Literature data Result: Negative Species: Rat Chromosomal Aberration Assay In Vivo; germ cells, Literature data Result: Negative Species: Hamster Dominant lethal assay, Literature data Result: Negative Species: Mouse
TITANIUM DIOXIDE		Micronucleus Assay in vitro, CHO cells, Literature data Result: Negative Micronucleus Assay in vitro, cultured human peripheral lymphocytes, Literature data Result: Positive

PROPAFENONE HYDROCHLORIDE

Micronucleus Assay, Literature data

Result: Negative

Species: Hamster

Micronucleus Assay, Literature data

Result: Negative

Species: Rat

Syrian Hamster Embryo (SHE) cell transformation assay

Result: Negative

WIL2-NS HPRT/ t-Thioguanidine - Human B-Cell

lymphoblastoid, Literature data

Result: Positive

TITANIUM DIOXIDE

Carcinogenicity

Health injuries are not known or expected under normal use. This product is not considered to be a carcinogen by IARC, ACGIH, NTP, or OSHA. Contains a material (titanium dioxide) classified as a carcinogen by external agencies. Carcinogenic activity was seen in inhalation studies using laboratory animals. High concentrations or doses administered over an extended period of time were required to produce adverse effects.

TITANIUM DIOXIDE

0.5 mg/m³, Literature data

Result: Negative

Species: Rat

Test Duration: 24 months

0.72 - 14.8 mg/m³, Literature data

Result: Negative

Species: Mouse

10 - 250 mg/m³, Dietary study - Literature data.

Result: Inflammation at all doses with alveolar/bronchiolar adenoma at the highest concentration.

Species: Rat

Test Duration: 24 months

2 year bioassay, Literature data

Result: Negative

Species: Mouse

2 year bioassay, Literature data

Result: Negative

Species: Rat

25000 - 50000 ppm, Dietary study

Result: Negative

Species: Mouse

25000 - 50000 ppm, Dietary study - Literature data.

Result: Negative

Species: Rat

7.2 - 14.8 mg/m³, Literature data

Result: Lung tumour

Species: Rat

Test Duration: 24 months

PROPAFENONE HYDROCHLORIDE

TITANIUM DIOXIDE

IARC Monographs. Overall Evaluation of Carcinogenicity

TITANIUM DIOXIDE (CAS 13463-67-7)

Reproductive toxicity

This product is not expected to cause reproductive or developmental effects.

PROPAFENONE HYDROCHLORIDE

Embryo-foetal development - Oral, Literature data

Result: LOAEL (foetal effects) = 15 mg/kg/day (increased post-implantation loss, no maternal effect)

Species: Rabbit

Embryo-foetal development - Oral, Literature data

Result: Maternal and foetal toxicity (no evidence of malformations) with dose of 150 mg/kg/day

Species: Rabbit

Embryo-foetal development - Oral, Literature data

Result: Maternal and foetal toxicity (no evidence of malformations) with doses of 600 mg/kg/day

Species: Rat

Embryo-foetal development - Oral, Literature data

Result: NOAEL (maternal and foetal) = 270 mg/kg/day

Species: Rat

Fertility, Literature data

Result: NOAEL (oral) / fertility = 270 mg/kg/day (maximum dose; 3X equivalent of recommended maximum human therapeutic dose)

Species: Rat

Specific target organ toxicity - single exposure None known.

Specific target organ toxicity - repeated exposure None known.

**Specific target organ toxicity -
repeated exposure**

PROPAFENONE HYDROCHLORIDE

Repeat dose non-clinical studies
Result: NOAEL = 90 mg/kg/day (equivalent to maximum recommended human dose); with doses of 180 mg/kg/day or more for 6 months adverse, but reversible, changes were observed in kidney; with doses of 270 mg/kg/day fatty degeneration of liver was observed
Species: Rat
Organ: kidney, liver

Aspiration hazard Not available.

12. Ecological information

Ecotoxicity Not expected to be harmful to aquatic organisms.

Components	Species	Test Results
MAGNESIUM STEARATE (CAS 557-04-0)		
Aquatic		
Acute		
Fish	EC50	Orange-red killfish (Adult <i>Oryzias latipes</i>)
Microtox	EC50	Microtox
TITANIUM DIOXIDE (CAS 13463-67-7)		
Aquatic		
Acute		
Crustacea	EC50	Water flea (<i>Daphnia magna</i>)
		> 1000 mg/l, 48 hours, Static test

* Estimates for product may be based on additional component data not shown.

Persistence and degradability

Photolysis

Half-life (Photolysis-atmospheric)

MAGNESIUM STEARATE 17 Hours Estimated

UV/visible spectrum wavelength

MAGNESIUM STEARATE 210 nm

Biodegradability

Percent degradation (Aerobic biodegradation-soil)

MAGNESIUM STEARATE 50 %, 13 days

Bioaccumulative potential

Bioconcentration factor (BCF)

MAGNESIUM STEARATE > 9999 Estimated

Mobility in soil

Adsorption

Soil/sediment sorption - log Koc

MAGNESIUM STEARATE 5.86 Estimated

Other adverse effects

Not available.

13. Disposal considerations

Disposal instructions

Collect and reclaim or dispose in sealed containers at licensed waste disposal site. Do not allow this material to drain into sewers/water supplies. Do not contaminate ponds, waterways or ditches with chemical or used container. Dispose of contents/container in accordance with local/regional/national/international regulations.

Local disposal regulations

Dispose in accordance with all applicable regulations.

Hazardous waste code

The waste code should be assigned in discussion between the user, the producer and the waste disposal company.

Waste from residues / unused products

Dispose of in accordance with local regulations. Empty containers or liners may retain some product residues. This material and its container must be disposed of in a safe manner (see: Disposal instructions).

Contaminated packaging

Empty containers should be taken to an approved waste handling site for recycling or disposal. Since emptied containers may retain product residue, follow label warnings even after container is emptied.

14. Transport information

DOT

Not regulated as a dangerous good.

IATA

Not regulated as a dangerous good.

IMDG

Not regulated as a dangerous good.

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code MARPOL Annex II applies to liquids used in a ship's operation that pose a threat to the marine environment. These materials may not be transported in bulk.

15. Regulatory information

US federal regulations

TSCA Section 12(b) Export Notification (40 CFR 707, Subpt. D)

Not regulated.

CERCLA Hazardous Substance List (40 CFR 302.4)

Not listed.

US. OSHA Specifically Regulated Substances (29 CFR 1910.1001-1050)

Not listed.

SARA 304 Emergency release notification

Not regulated.

Superfund Amendments and Reauthorization Act of 1986 (SARA)

Hazard categories	Immediate Hazard - Yes Delayed Hazard - Yes Fire Hazard - No Pressure Hazard - No Reactivity Hazard - No
--------------------------	--

SARA 302 Extremely hazardous substance	No
---	----

SARA 311/312 Hazardous chemical	No
--	----

Other federal regulations

Clean Air Act (CAA) Section 112 Hazardous Air Pollutants (HAPs) List

Not regulated.

Clean Air Act (CAA) Section 112(r) Accidental Release Prevention (40 CFR 68.130)

Not regulated.

Safe Drinking Water Act (SDWA)	Not regulated.
---------------------------------------	----------------

Food and Drug Administration (FDA)	Not regulated.
---	----------------

US state regulations

US. Massachusetts RTK - Substance List

STARCK (CAS 9005-25-8)
TITANIUM DIOXIDE (CAS 13463-67-7)

US. New Jersey Worker and Community Right-to-Know Act

Not regulated.

US. Pennsylvania RTK - Hazardous Substances

STARCK (CAS 9005-25-8)
TITANIUM DIOXIDE (CAS 13463-67-7)

US. Rhode Island RTK

Not regulated.

US. California Proposition 65

WARNING: This product contains a chemical known to the State of California to cause cancer.

US - California Proposition 65 - CRT: Listed date/Carcinogenic substance

TITANIUM DIOXIDE (CAS 13463-67-7) Listed: September 2, 2011

International Inventories

Country(s) or region	Inventory name	On inventory (yes/no)*
Australia	Australian Inventory of Chemical Substances (AICS)	No
Canada	Domestic Substances List (DSL)	No

Country(s) or region	Inventory name	On inventory (yes/no)*
Canada	Non-Domestic Substances List (NDSL)	No
China	Inventory of Existing Chemical Substances in China (IECSC)	No
Europe	European Inventory of Existing Commercial Chemical Substances (EINECS)	No
Europe	European List of Notified Chemical Substances (ELINCS)	No
Japan	Inventory of Existing and New Chemical Substances (ENCS)	No
Korea	Existing Chemicals List (ECL)	No
New Zealand	New Zealand Inventory	No
Philippines	Philippine Inventory of Chemicals and Chemical Substances (PICCS)	No
United States & Puerto Rico	Toxic Substances Control Act (TSCA) Inventory	No

*A "Yes" indicates that all components of this product comply with the inventory requirements administered by the governing country(s).
A "No" indicates that one or more components of the product are not listed or exempt from listing on the inventory administered by the governing country(s).

16. Other information, including date of preparation or last revision

Issue date	11-01-2013
Revision date	11-01-2013
Version #	02
Further information	Not available.
References	GSK Hazard Determination
Disclaimer	The information and recommendations in this safety data sheet are, to the best of our knowledge, accurate as of the date of issue. Nothing herein shall be deemed to create any warranty, express or implied. It is the responsibility of the user to determine the applicability of this information and the suitability of the material or product for any particular purpose.
Revision Information	Product and Company Identification: Business Units Composition / Information on Ingredients: Ingredients Transport Information: Agency Name, Packaging Type, and Transport Mode Selection Regulatory Information: United States GHS: Classification